Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Newcastle-upon-Tyne Hospitals NHS Trust
With
University of Newcastle Upon-Tyne
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\) Histologic or cytologic diagnosis of breast cancer or colorectal cancer. Patients should have disease that is suitable for capecitabine monotherapy as defined by the NICE Guidelines.
2\) Patients must be within the first week of their first cycle of capecitabine treatment.
3\) Estimated life expectancy of greater than 3 months. 4) Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. 5) Total serum bilirubin less than or equal to 25 micromol/L. 6) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels less than 2.5 times the upper limit of the normal range.
7\) Serum albumin level greater than 32 g/L. 8) Creatinine clearance greater than or equal to 30 mL/minute. 9) Blood haemoglobin level of greater than 9 g/dL, with transfusion allowed. 10) Absolute neutrophil count greater than 2.5 x 109/L. 11) Platelet count greater than 100 x 109/L. 12) 18 years of age or older. 13) Written informed consent.
You may not be if
1. Pregnancy or breast feeding.
2. Known HIV, Hepatitis B, or Hepatitis C infection.
3. Known Gilbert syndrome.
4. Uncontrolled diabetes (HbA1c greater than 7.5%).
5. Any condition or disease that might affect oral absorption of medications, including:
1. Crohn's disease
2. Ulcerative colitis
3. Major gastric or small bowel resection
\-
Clareo Health | Association of Capecitabine Pharmacokinetics and Toxicity With Aging
